{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:43:15Z","timestamp":1790390595437,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.nmd.2019.09.014","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T02:08:21Z","timestamp":1569463701000},"page":"819-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes"],"prefix":"10.1016","volume":"29","author":[{"given":"Albert","family":"Selva-O'Callaghan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Gil-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Vila-Pijoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Trallero-Aragu\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Pinal-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2019.09.014_bib0001","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0002","series-title":"An elusive diagnosis with a risk of cancer","author":"Caryn Rabin","year":"2007"},{"key":"10.1016\/j.nmd.2019.09.014_bib0003","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/BOR.0b013e32833f1075","article-title":"Malignancy and myositis: novel autoantibodies and new insights","volume":"22","author":"Selva-O'Callaghan","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0004","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy. a population-based cohort study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nmd.2019.09.014_bib0006","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis. a population-based study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.09.014_bib0007","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2019.09.014_bib0008","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2019.09.014_bib0009","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2019.09.014_bib0010","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.nmd.2019.09.014_bib0011","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2019.09.014_bib0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.semarthrit.2015.06.005","article-title":"Survival and cancer risk in an & unselected and complete norwegian idiopathic inflammatory myopathy cohort","volume":"45","author":"Dobloug","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0013","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"IIM study group and autoimmune diseases study group (GEAS) of the Spanish society of internal medicine (SEMI). Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0014","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the antisynthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.nmd.2019.09.014_bib0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2019.09.014_bib0016","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.24977","article-title":"Expression of the dermatomyositis autoantigen MI-2 in regenerating muscle","volume":"60","author":"Mammen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0017","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.38863","article-title":"Expression of the dermatomyositis autoantigen transcription intermediary factor 1\u03b3 in regenerating muscle","volume":"67","author":"Mohassel","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0018","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0019","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.40883","article-title":"Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity","volume":"71","author":"Pinal-Fernandez","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00005792-199203000-00001","article-title":"Anti-Hu\u2013associated paraneoplastic encephalomyelitis\/sensory neuronopathy. a clinical study of 71 patients","volume":"71","author":"Dalmau","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2019.09.014_bib0021","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/WNL.42.10.1931","article-title":"Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients","volume":"42","author":"Peterson","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.09.014_bib0022","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/01.bor.0000245721.02512.77","article-title":"Cancer and myositis: new insights into an old association","volume":"18","author":"Levine","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0023","doi-asserted-by":"crossref","first-page":"E1962","DOI":"10.3390\/ijms20081962","article-title":"The pathway to cancer cachexia: microRNA-Regulated networks in muscle wasting based on integrative meta-analysis","volume":"20","author":"Freire","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmd.2019.09.014_bib0024","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"Childhood myositis heterogeneity study group; international myositis collaborative study group. a novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.09.014_bib0026","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2019.09.014_bib0027","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","article-title":"for the juvenile dermatomyositis research group UK. Clinical associations of autoantibodies to a p155\/140kDa doublet protein in juvenile dermatomyositis","volume":"47","author":"Gunawardena","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.09.014_bib0028","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/03009740802687455","volume":"38","author":"Fujikawa","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0029","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MD.0b013e3181ca14ff","article-title":"Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy","volume":"89","author":"Trallero-Araguas","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2019.09.014_bib0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0031","article-title":"Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-\u03b3) in dermatomyositis [abstract]","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0032","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0033","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2019.09.014_bib0034","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/1756-185X.13424","article-title":"Anti-TIF1\u03b3 antibody and the expression of TIF1\u03b3 in idiopathic inflammatory myopathies","volume":"22","author":"Kim","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.nmd.2019.09.014_bib0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/ced.13180","article-title":"Expression of the autoantigen TRIM33\/TIF1\u03b3 in skin and muscle of patients with dermatomyositis is upregulated, together with markers of cellular stress","volume":"42","author":"Scholtissek","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0036","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3139","article-title":"TRIM proteins and cancer","volume":"11","author":"Hatakeyama","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nmd.2019.09.014_bib0037","first-page":"990","article-title":"Strong correlation between cancer progression and anti-transcription intermediary factor 1\u03b3 antibodies in dermatomyositis patients","volume":"36","author":"Ogawa-Momohara","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0038","article-title":"Anti-transcriptional intermediary factor1 gamma antibodies in cancer-associated myositis: a longitudinal study","author":"Dani","year":"2019","journal-title":"Clin Exp Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0039","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.nmd.2019.09.014_bib0040","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2019.09.014_bib0041","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.09.014_bib0042","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.nmd.2019.09.014_bib0043","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.09.014_bib0044","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nmd.2019.09.014_bib0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.nmd.2019.09.014_bib0046","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilumab in lung cancer with high tumor mutational burden","volume":"378","author":"Hellman","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.09.014_bib0047","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.nmd.2019.09.014_bib0048","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.170544","article-title":"Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis","volume":"45","author":"Chen","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0049","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed death-1 pathway in cancer and autoimmunity","volume":"153","author":"Pedoeem","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cyto.2014.11.026","article-title":"The role of type I interferons and other cytokines in dermatomyositis","volume":"73","author":"Arshanapalli","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.nmd.2019.09.014_bib0051","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.09.014_bib0052","first-page":"4155","article-title":"Tumor infiltrating lymphocytes: the regulator of melanoma evolution","volume":"17","author":"Antohe","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.nmd.2019.09.014_bib0053","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.nmd.2019.09.014_bib0054","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.4049\/jimmunol.1801022","article-title":"Identification of neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer","volume":"202","author":"Leko","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2019.09.014_bib0055","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.nmd.2019.09.014_bib0056","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1007\/s13277-016-4812-9","article-title":"Potential biomarker for checkpoint blockade immunotherapy and treatment strategy","volume":"37","author":"Dong","year":"2016","journal-title":"Tumour Biol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896619311344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896619311344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:09:05Z","timestamp":1760774945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896619311344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0960896619311344"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2019.09.014","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2019.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}